Efficacy and safety of autologous tumor-infiltrating lymphocytes in recurrent or refractory ovarian cancer, colorectal cancer, and pancreatic ductal adenocarcinomaRodabe N. Amaria, Amir A. Jazaeri, Anne Knisely et al.|Journal for ImmunoTherapy of Cancer|2024Cited by 54
PPP2R1A mutations portend improved survival after cancer immunotherapyYibo Dai, Amir A. Jazaeri, Sanghoon Lee et al.|Nature|2025Cited by 30
Randomized phase 2 trial of tremelimumab and durvalumab in combination versus sequentially in recurrent platinum‐resistant ovarian cancerEmily Hinchcliff, Amir A. Jazaeri, Anne Knisely et al.|Cancer|2023Cited by 18
Phase 1/2 trial of avelumab combined with utomilumab (4‐1BB agonist), PF‐04518600 (OX40 agonist), or radiotherapy in patients with advanced gynecologic malignanciesAnne Knisely, Aung Naing, Jibran Ahmed et al.|Cancer|2023Cited by 17
Surgical and Blood-Based Minimal Residual Disease in Patients with Ovarian Cancer after First-line Therapy: Clinical Outcomes and Translational OpportunitiesAnne Knisely, Amir A. Jazaeri, Yibo Dai et al.|Clinical Cancer Research|2025Cited by 10